B2BROKER
25.3.2024 19:16:31 CET | Business Wire | Press release
The crypto market is on an exciting growth journey, with Bitcoin hitting all-time highs and the total crypto market cap exceeding $2.37T. This coincides with the introduction of MiCA regulation, effective June 30, 2024, and followed by another wave on December 30, 2024, aiming to increase credibility and transparency, fostering wider crypto adoption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325324392/en/
B2Broker releases B2Trader, an industry-leading crypto spot brokerage solution. (Graphic: Business Wire)
With over 20,000 coins and tokens and a user base of over 300 million traders, compared to the FX market's 128 currency pairs and estimated 50 million traders, crypto is emerging as a more appealing trading option. Its expansion is fueled by its broad adaptation across finance, fintech, payments, and other sectors. Introducing innovative business models through technologies like L2 solutions and blockchain protocols.
To meet the booming crypto trading demand, brokerages are actively seeking solutions to enter the market. And in response, B2Broker announces the release of the B2Trader Brokerage Platform (BBP), a crypto spot broker solution designed to help businesses tap into this growing trend and start generating revenue faster than ever!
Who Can Benefit from B2Trader?
B2Trader is a powerful solution for crypto brokers (CFD and Derivatives), OTC brokers, FOREX brokers, multi-asset and multi-market brokers, market makers, liquidity providers, payment systems, and even banks to follow the market trends and enter the fastest-growing industry.
Here’s how each business model is able to utilise BBP:
FOREX Brokers
B2Trader can be an excellent addition to any FX broker. Along with the traditional trading platforms (MT4, MT5, cTrader, etc.) that mainly handle assets like FX, crypto, equity indices, and precious metals for margin trading or in the form of CFDs, you can add B2Trader to offer crypto spot trading exclusively, attract a new segment of crypto traders interested in physical delivery or ownership, and generate revenue through commissions, markups, and effective risk management.
Additionally, BBP offers a solution for regulated FX brokers to separate their digital asset trading under a different license, promoting strategic diversification and maintaining a competitive advantage in today’s market.
Crypto Brokers
Brokers focusing on crypto CFDs, using crypto as collateral, and offering a mix of FX and crypto CFDs can use B2Trader to enhance existing solutions with crypto spot trading.
Given the competitive nature of client retention and acquisition, the absence of crypto spot trading options could lead clients to seek services elsewhere. Thus, integrating B2Trader is a strategic advantage for brokerages, allowing them to adapt to market trends swiftly, offer much-demanded crypto spot trading, and meet client expectations.
Market Makers
Market makers can use B2Trader to access multiple exchanges, consolidate liquidity efficiently, achieve competitive spreads, optimise pricing, and enable smart routing execution across different venues.
Liquidity Providers
Adding cryptocurrencies to your asset offerings greatly boosts your appeal to brokers, hedge funds and professional traders. B2Trader streamlines this process, equipping you with the essential tools to expand your market reach and accelerate your earnings.
EMIs, Payment Systems, and Banks
For EMIs, PSPs, and banks, B2Trader provides a strategic edge by enabling diverse asset management, monitoring, and liquidity pool creation. It allows these entities to add crypto services to their existing operations, net all transactions, offer crypto accounts, and enable instant swaps.
BBP opens unlimited opportunities as your gateway to crypto and its booming trends. With its comprehensive API and a complete set of essential components and modules, B2Trader seamlessly integrates into any business model.
High-Speed, High-Efficiency, High-Tech
B2Trader is designed for the Enterprise scale of brokers to serve modern financial markets. Even in its most basic setup, it handles 3000 trading instruments and processes up to 3000 requests per second. It offers real-time market data, updates every 100 ms and ultra-fast order execution starting from 1 ms. This can be improved further by enhancing cloud resources and computing.
"Today, B2Broker is a leading name in the FinTech industry. We began operating in the FOREX industry in 2014 and have been developing solutions for the crypto industry since 2017. B2Broker has earned multiple awards and recognitions, and our years of experience have allowed us to understand what the market needs exactly.
That's why we created B2Trader. It's our answer to the changing trends in finance. We have poured 18 months of hard work and over $5 million into B2Trader. BBP is built by our dedicated in-house team of 40 engineers, each contributing to a solution that truly meets the demands of today's brokers. In the next 12 months, we are planning to double the team and enhance our offerings even further!"
— Arthur Azizov, CEO and Founder of B2Broker
Cutting-Edge Technology Stack
BBP focuses on reliability, scalability, and security, using the latest tools and protocols. It is hosted on AWS for its dependable infrastructure, reducing hardware risks. It utilises MongoDB and Amazon Redshift for data management and includes TradingView for market insights.
Kubernetes and Docker support scalable deployments, while CloudFlare provides DDoS protection. The FIX protocol boosts B2Trader's efficiency and reliability.
Powerful Integrations
Developed by B2Broker, B2Trader offers powerful integrations. B2Broker offers a comprehensive suite of products, including a trading platform, OMS, pre-trade and post-trade control, liquidity management system, Trading User Interface, CRM, back office, blockchain wallets for processing and collecting coins/tokens, blockchain management system for automatic payouts and settlements, mobile applications, technical documentation, REST and FIX API protocols, advanced White Label options, and much more.
Additionally, integrated with Marksman, a crypto liquidity distribution engine, B2Trader streamlines administration and ensures market updates with the latest data.
With Marksman, crypto brokers swiftly link to top exchanges by inputting API credentials after opening an account. This allows brokers to create diverse liquidity pools from various exchanges, assign specific execution and routing rules, and establish failover protocols for both the pairs and the liquidity pools.
B2Trader is available as a turnkey solution or for integration with any CRM via REST API. Contact the sales team or your account manager, try out the free demo, and launch your crypto spot broker within a week!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325324392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom